Generic Name and Formulations:
Dalfampridine 10mg; ext-rel tabs.
Indications for AMPYRA:
To improve walking in patients with multiple sclerosis (demonstrated by an increase in walking speed).
Swallow whole. ≥18yrs: max 10mg every 12hrs.
<18yrs: not established.
History of seizures. Moderate to severe renal impairment (CrCl ≤50mL/min). Previous allergies to 4-aminopyridine.
Assess renal function before initiation; monitor at least annually. Mild renal impairment (CrCl 51–80mL/min): increased risk of seizures. Discontinue if signs/symptoms of anaphylaxis occurs. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.
Potassium channel blocker.
Discontinue other forms of 4-aminopyridine prior to initiating. Concomitant OCT2 inhibitors (eg, cimetidine) may potentiate the risk of seizures.
UTI, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, MS relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, throat pain; seizures (possible at higher doses), severe allergic reactions.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- ADHD Medications Compared for Efficacy, Tolerability in Children and Adults
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation